<SEC-DOCUMENT>0001140361-25-044950.txt : 20251209
<SEC-HEADER>0001140361-25-044950.hdr.sgml : 20251209
<ACCEPTANCE-DATETIME>20251209092428
ACCESSION NUMBER:		0001140361-25-044950
CONFORMED SUBMISSION TYPE:	POSASR
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251209
DATE AS OF CHANGE:		20251209
EFFECTIVENESS DATE:		20251209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POSASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279338
		FILM NUMBER:		251557787

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-487-6488

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>POSASR
<SEQUENCE>1
<FILENAME>ef20060810_posasr.htm
<DESCRIPTION>POSASR
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: center; color: #000000; font-weight: bold;">As filed with the Securities and Exchange Commission on December 9, 2025</div>
  <div><br>
  </div>
  <div style="text-align: right; color: #000000; font-weight: bold;">Registration No. 333-279338</div>
  <div style="text-align: right; color: #000000; font-weight: bold;">
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
  <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
  <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
  <div style="text-align: center; color: #000000; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
    </font></div>
  <div>
    <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
  <div><br>
  </div>
  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">POST-EFFECTIVE AMENDMENT NO. 1</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">TO</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">FORM S-3 REGISTRATION STATEMENT NO. 333-279338</div>
  <div><br>
  </div>
  <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">UNDER</div>
  <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
  <div><br>
  </div>
  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 24pt;">AKERO THERAPEUTICS, INC.</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">(Exact name of Registrant as specified in its charter)</div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
  <div> <br>
  </div>
  <table cellspacing="0" cellpadding="0" border="0" id="z8ce08dd66b0046fe8afe0ba0a19b7795" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

      <tr>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware</div>
        </td>
        <td style="width: 2%; vertical-align: top;">&#160;</td>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">81-5266573</div>
        </td>
      </tr>
      <tr>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or jurisdiction of incorporation or organization)</div>
        </td>
        <td style="width: 2%; vertical-align: top;">&#160;</td>
        <td style="width: 49%; vertical-align: top;">
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(I.R.S. Employer Identification Number)</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: center; color: #000000; font-weight: bold;">601 Gateway Boulevard, Suite 350</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">South San Francisco, CA 94080</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">(650) 487-6488</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant&#8217;s Principal Executive Offices)</div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 25%; color: #000000; text-align: center;"></div>
  <div><br>
  </div>
  <div style="text-align: center; color: #000000; font-weight: bold;">Jonathan Young, J.D., Ph.D.</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">Assistant Treasurer</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">601 Gateway Boulevard, Suite 350</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">South San Francisco, CA 94080</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">(650) 487-6488</div>
  <div style="text-align: center; color: #000000; font-weight: bold;">(Name, Address, and Telephone Number, including Area Code, of Agent for Service)</div>
  <div><br>
  </div>
  <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">Copies to:</div>
  <div><br>
  </div>
  <div style="text-align: center; font-weight: bold;">Christopher Comeau</div>
  <div style="text-align: center; font-weight: bold;">Emily Oldshue</div>
  <div style="text-align: center; font-weight: bold;">Ropes &amp; Gray LLP</div>
  <div style="text-align: center; font-weight: bold;">Prudential Tower, 800 Boylston Street</div>
  <div style="text-align: center; font-weight: bold;">Boston, Massachusetts 02199</div>
  <div style="text-align: center; font-weight: bold;">(617) 951-7000<br>
    <br>
  </div>
  <div style="text-align: center; font-weight: bold;">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"> </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="color: #000000;">Approximate date of commencement of proposed sale to the public: <font style="font-weight: bold;">Not applicable.</font></div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: &#9744;</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in
    connection with dividend or interest reinvestment plans, check the following box: &#9744;</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement
    number of the earlier effective registration statement for the same offering. &#9744;</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
    effective registration statement for the same offering. &#9744;</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e)
    under the Securities Act, check the following box. &#9746;</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to
    Rule 413(b) under the Securities Act, check the following box. &#9744;</div>
  <div><br>
  </div>
  <div style="text-align: justify; color: #000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
    of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" id="zd3154f87c2734cfcb6bc7f376f571b51" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

      <tr>
        <td style="width: 41.5%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">Large accelerated filer</div>
        </td>
        <td style="width: 4%; vertical-align: bottom;">&#9746;</td>
        <td style="width: 50.51%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">Accelerated filer</div>
        </td>
        <td style="width: 4%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">&#9744;</div>
        </td>
      </tr>
      <tr>
        <td style="width: 41.5%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">Non-accelerated filer</div>
        </td>
        <td style="width: 4%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">&#9744;</div>
        </td>
        <td style="width: 50.51%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">Smaller reporting company</div>
        </td>
        <td style="width: 4%; vertical-align: bottom;">&#9744;</td>
      </tr>
      <tr>
        <td style="width: 41.5%; vertical-align: bottom;">&#160;</td>
        <td style="width: 4%; vertical-align: bottom;">&#160;</td>
        <td style="width: 50.51%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">Emerging growth company</div>
        </td>
        <td style="width: 4%; vertical-align: bottom;">
          <div style="color: rgb(0, 0, 0);">&#9744;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="color: #000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
    7(a)(2)(B) of the Securities Act. &#9744;</div>
  <div><br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; color: #000000; font-weight: bold;">DEREGISTRATION OF SECURITIES</div>
  <div><font style="color: #000000;"> </font><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Post-Effective Amendment (the &#8220;<u>Post-Effective Amendment</u>&#8221;) relates to the following Registration Statement on Form S-3 (the &#8220;<u>Registration Statement</u>&#8221;) filed by Akero
    Therapeutics, Inc. (&#8220;<u>Akero</u>&#8221; or the &#8220;<u>Company</u>&#8221;) with the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;):</div>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" id="z711683a522c746ac8a5dfbb78e758b91" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 18pt; vertical-align: top;">&#8226;</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Registration Statement No. 333-279338, originally filed with the SEC on May 10, 2024, relating to the registration of (i) an indeterminate number of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;<u>Common Stock&#8221;</u>), of up to a
            maximum aggregate offering price of $261,722,722 pursuant to the Open Market Sale Agreement, dated as of March 17, 2023, as amended May 10, 2024, by and between the Company and Jefferies LLC, as sales agent, and (ii) an indeterminate number of
            Common Stock, preferred stock, par value $0.0001 per share, debt securities, warrants and/or units.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">On December 9, 2025 (the &#8220;<u>Effective Date</u>&#8221;), NN Invest Sub, Inc, a Delaware corporation (<u>&#8220;Merger Sub</u>&#8221;) and a direct or indirect wholly owned subsidiary
      of Novo Nordisk A/S, a Danish <font style="font-style: italic;">aktieselskab</font> (&#8220;<u>Novo</u>&#8221;), completed its merger (the &#8220;<u>Merger</u>&#8221;) with and into Akero pursuant to the terms of the Agreement and Plan of Merger, dated October 9, 2025 (the
      &#8220;<u>Merger Agreement</u>&#8221;), by and among Novo, Merger Sub, and Akero. Akero was the surviving corporation in the Merger and, as a result, is now a wholly owned subsidiary of Novo.</font></div>
  <div><br>
  </div>
  <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">As a result of the Merger, Akero has terminated all offerings and sales of securities pursuant to the Registration Statement. In accordance with an undertaking made by Akero in the
    Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance under the Registration Statement that remain unsold at the termination of such offering, Akero
    hereby removes from registration all of such securities registered but remaining unsold under the Registration Statement as of the Effective Date. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such
    securities. After giving effect to the Post-Effective Amendment, there will be no remaining securities registered by Akero pursuant to the Registration Statement.</div>
  <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 27pt;"> <br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
  <div><font style="color: #000000;"> </font><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; color: #000000;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
    S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this 9th day of December, 2025.</div>
  <div style="text-align: justify;"><font style="color: #000000;"> </font><br>
  </div>
  <div style="text-align: justify;"><font style="color: #000000;"> </font>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 9pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="vertical-align: bottom; font-size: 10pt; width: 4%;" rowspan="1" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; font-size: 10pt;" rowspan="1" colspan="3">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">AKERO THERAPEUTICS, INC.</div>
          </td>
          <td style="width: 72%; vertical-align: bottom;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 4%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 1%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 20%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 72%; vertical-align: bottom;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 4%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 1%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 20%; vertical-align: bottom; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 72%; vertical-align: bottom;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 4%; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 1%; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td nowrap="nowrap" style="width: 20%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="margin-bottom: 1pt; color: rgb(0, 0, 0); font-size: 10pt;">/s/ Jonathan Young, J.D., Ph.D.</div>
            </div>
          </td>
          <td style="width: 72%; vertical-align: bottom; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 4%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 20%; vertical-align: bottom; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Name: Jonathan Young, J.D., Ph.D.</div>
          </td>
          <td style="width: 72%; vertical-align: bottom; font-size: 10pt;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 4%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td nowrap="nowrap" style="width: 20%; vertical-align: bottom; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Title: Assistant Treasurer</div>
          </td>
          <td nowrap="nowrap" style="width: 72%; vertical-align: bottom; font-size: 10pt;"><br>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div style="color: #000000;">No other person is required to sign this Post-Effective Amendment in reliance on Rule 478 of the Securities Act of 1933.</div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
